Mount Sinai Researchers Uncover a Neural Pathway that is Critical to Correcting Behavioral Errors Relevant to Many Psychiatric Disorders
Mount Sinai researchers have identified a neural pathway through which the brain detects errors and guides subsequent behavioral improvement. This process, called cognitive control, is frequently dysregulated in a wide range of psychiatric disorders. The team’s research, published February 19 in Neuron, also suggests that neurostimulation of this brain pathway could provide an important mechanism for attention adjustments following behavioral errors.
When errors are committed, such as missing a stop sign or running a red light while driving, it’s important for our survival to immediately adapt behavior by paying more attention to prevent further errors. This ability to adapt behavior after erroneous actions is one of the key components of human cognitive control.
“Deficits in error monitoring and attentional function are common to many psychiatric problems, including schizophrenia, ADHD, and autism spectrum disorder, but little is known about the specific neural pathways that are linking these processes,” says senior author Hirofumi Morishita, MD, PhD, Associate Professor of Psychiatry, Neuroscience, and Ophthalmology, and a faculty member of The Friedman Brain Institute and the Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai. “Our study, conducted in mice and led by Kevin Norman, a graduate student in our laboratory, represents the first demonstration of a specific circuit mechanism linking error-monitoring and attentional adjustment, two fundamental components of cognitive control systems in humans.”
The neural basis of cognitive control has been a hotly debated topic within neuroscience, with a host of neuroimaging studies showing that parts of the frontal cortex, which is pivotal to planning appropriate behavioral responses to external and internal stimuli, are essential for error monitoring.
The new Mount Sinai study took that finding an important step further. In a series of experiments with mice, allowing for deployment of a full suite of neuroscience techniques not possible in humans, the researchers discovered a specific neural pathway originating in the frontal cortex that is engaged during a key aspect of cognitive control.
Specifically, they learned that task-related errors recruit frontal neurons that project signals onto the visual cortex, which processes visual information from the eye, and that this post-error activation is essential for improving subsequent behavioral performance.
“Frontal projections to visual areas are important for attention modulation of visual processing,” explains Dr. Morishita. “Put another way, we showed that direct and specific frontal sensory projections are key pathways for linking past errors to cognitive control mechanisms that promote attention.”
Beyond its enhanced mapping of the neural circuit and function, the Mount Sinai study could have major implications for clinical treatment. The team employed a technique known as optogenetic stimulation, a biological process that employs a combination of genetic and light techniques to control the activities of individual neurons to selectively stimulate the frontal projections to the visual cortex. By employing this technique, the researchers were able to improve attention in these mice once light pulses were administered to them after errors. The specific cortical pathway identified in this study could potentially be modulated using techniques like transcranial magnetic stimulation and/or transcranial direct current stimulation to improve post-error attentional adjustments in many of the most common types of psychiatric disorders.
“On a larger scale, our findings resolve the conflicts among recent studies reporting mixed contributions of frontal-sensory circuits to attentional behavior by suggesting that this circuit is only recruited under certain conditions, namely following task-related errors,” says Dr. Morishita. “For that reason, we believe our research will have broad interest and impact the fields of neuroscience, psychology, psychiatry, and neurology, while informing neuroscience-based computational models of cognition.”
This work was supported by the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative of the National Institutes of Health, the National Institute of Mental Health and the National Eye Institute.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.